Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Chlorpromazine
Drug ID BADD_D00445
Description The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
Indications and Usage For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.
Marketing Status approved; investigational; vet_approved
ATC Code N05AA01
DrugBank ID DB00477
KEGG ID D00270
MeSH ID D002746
PubChem ID 2726
TTD Drug ID D01ZII
NDC Product Code 62332-735; 70518-3175; 63304-083; 63304-114; 62332-738; 62332-737; 63304-122; 62332-739; 63304-143; 62332-736; 63304-185
UNII U42B7VYA4P
Synonyms Chlorpromazine | Thorazine | Aminazine | Largactil | Chlordelazine | Chlorpromazine Hydrochloride | Hydrochloride, Chlorpromazine | Contomin | Fenactil | Propaphenin | Chlorazine
Chemical Information
Molecular Formula C17H19ClN2S
CAS Registry Number 34468-21-8
SMILES CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tremor17.01.06.002--
Trismus15.05.04.004; 17.01.03.004--
Unresponsive to stimuli17.02.05.0310.000677%Not Available
Urinary incontinence20.02.02.010; 17.05.01.0080.000677%
Urinary retention20.02.02.011--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred06.02.06.007; 17.17.01.010--
Visual impairment06.02.10.013--Not Available
Mental status changes19.07.01.0010.000677%Not Available
Brain oedema17.07.02.003; 12.01.10.010--
Conjunctival hyperaemia06.04.01.0040.000677%Not Available
Acquired haemophilia01.01.01.0020.001355%Not Available
Faecaloma07.01.03.004--Not Available
Parkinsonian rest tremor17.01.05.009--Not Available
Erectile dysfunction21.03.01.007; 19.08.04.001--
Blood disorder01.05.01.004--Not Available
Disease recurrence08.01.03.0500.000677%Not Available
Pigmentation disorder23.05.03.001--Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.000677%Not Available
Oropharyngeal discomfort07.05.05.008; 22.12.03.015--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Drug-induced liver injury12.03.01.044; 09.01.07.0230.000677%Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 12.03.01.064; 10.01.01.0210.000677%Not Available
Dermatitis exfoliative generalised10.01.01.029; 23.03.07.002--Not Available
Sopor19.02.04.002; 17.02.04.0210.000677%Not Available
Heavy menstrual bleeding21.01.03.005--Not Available
Hepatic cytolysis09.01.07.0360.000677%Not Available
Reduced facial expression17.01.05.016; 19.01.02.021--Not Available
The 6th Page    First    Pre   6    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene